RSCM
PHAS

Rock Springs Capital Management’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Rock Springs Capital Management’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,719,074
Closed -$479K – 127
2022
Q3 		$479K Sell
2,719,074
-55,795
-2% -$56.9K 0.01% 125
2022
Q2 		$1.67M Buy
2,774,869
+161,044
+6% +$154K 0.05% 117
2022
Q1 		$3.45M Buy
2,613,825
+32,526
+1% +$52.7K 0.09% 112
2021
Q4 		$6.74M Buy
2,581,299
+737,535
+40% +$2.23M 0.16% 108
2021
Q3 		$5.73M Hold
1,843,764
– – 0.12% 124
2021
Q2 		$6.86M Buy
1,843,764
+289,790
+19% +$965K 0.14% 128
2021
Q1 		$5.38M Buy
1,553,974
+239,600
+18% +$972K 0.12% 131
2020
Q4 		$4.42M Buy
1,314,374
+1,200
+0.1% +$4.3K 0.09% 139
2020
Q3 		$4.61M Buy
1,313,174
+169,249
+15% +$682K 0.12% 131
2020
Q2 		$5.26M Buy
1,143,925
+18,925
+2% +$83.8K 0.14% 129
2020
Q1 		$3.72M Hold
1,125,000
– – 0.15% 111
2019
Q4 		$6.87M Sell
1,125,000
-291,900
-21% -$1.2M 0.22% 97
2019
Q3 		$5.91M Sell
1,416,900
-6,356
-0.4% -$50.7K 0.24% 96
2019
Q2 		$18.7M Buy
1,423,256
+283,256
+25% +$3.47M 0.68% 54
2019
Q1 		$10.8M Buy
1,140,000
+305,000
+37% +$1.21M 0.42% 75
2018
Q4 		$2.58M Buy
+835,000
New +$3.31M 0.12% 118

Other funds holding PHAS

DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HLA
Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return
IIA
IPG Investment Advisors San Diego, California $582M AUM 33.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Rock Springs Capital Management's PHAS Position: Q4 2022 in Review

Rock Springs Capital Management sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2022, closing a stake of 2,719,074 shares — an estimated $479K sold.

Rock Springs Capital Management first reported a position in PHAS in Q4 2018 and held it in 16 quarters. The position peaked at $18.7M in Q2 2019. 5 funds tracked by Wall St. Rank hold PHAS as of Q4 2022.

  • Rock Springs Capital Management reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Rock Springs Capital Management sold 2,719,074 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $479K.
  • Rock Springs Capital Management first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q4 2018 and held it in 16 quarters.
  • Rock Springs Capital Management's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $18.7M in Q2 2019.
  • 5 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Rock Springs Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.